Lantern Pharma Inc. Common Stock
LTRNStock
$2.91−23.06%52W
Market Cap$38.91M
P/E—
Div yield—
Beta2.31
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-19.69%
Price vs S&P 500 (4W)-16.40%
VGM Score60.32
Market Capitalization$38.91M
Earnings Surprise History
Q1 26-0.30est. -0.37
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
4.14
4.14
4.14
4.14
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
LTRNLantern Pharma Inc. Common Stock | — | — | B | $2.91 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
Lantern Pharma uses artificial intelligence to accelerate oncology drug discovery and development. The company's proprietary RADR platform applies machine learning to oncology-focused data, reducing drug development costs and timelines. Its growing pipeline of precision cancer therapies is powered by AI-driven insights and partnerships with leading scientific experts.